RxDoctor Payments Data

Ryan Harvey

Acute Care · Nampa, IDNPI 1023516911

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 25.6% of the total.

$1,429in general payments, 2019–2025

Across 22 payments — averaging $64.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$367
  • Amgen$253
  • Boston Scientific$242
  • Novo Nordisk$179
  • AstraZeneca$125
  • E.r. Squibb & Sons, L.L.C.$123
  • plus $142 from 2 others

What the payments were for

  • Food & beverage$1,41599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 80th percentile of 35 acute care providers in Idaho.

See all acute care providers in Idaho

Medicare billing

Part B allowed, 2024
$41,004
Medicare patients
410
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban502$653,556
Repatha SureclickEvolocumab76$86,657
JardianceEmpagliflozin29$44,293
FarxigaDapagliflozin Propanediol32$36,131
XareltoRivaroxaban20$27,007
OzempicSemaglutide12$22,261
Metoprolol Succinate567$8,835
Atorvastatin Calcium535$6,574
Ranolazine ErRanolazine34$5,418
Diltiazem 24hr Er (Cd)Diltiazem Hcl117$4,235
Amiodarone Hcl38$3,241
Ezetimibe119$2,646
Isosorbide Mononitrate ErIsosorbide Mononitrate182$2,425
Losartan Potassium215$2,288
Lisinopril240$2,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$125$36,13132 claims
Novo NordiskOzempic$179$22,26112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 acute care providers in Idaho.

Other acute care in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →